Ondansetron Medley Pharma

Ondansetron, the active ingredient in Ondansetron Medley Pharma, is a 5-HT3 receptor antagonist presented as a oral dosage form for oral use. It treats nausea and vomiting associated with chemotherapy, postoperative settings, and radiotherapy in patients who require antiemetic therapy.

GNH USA supplies Ondansetron Medley Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron acts on the serotonin 5‑HT3 receptors to prevent nausea and vomiting in several clinical settings. - Chemotherapy‑induced nausea and vomiting: prevents and controls nausea and vomiting in patients receiving cytotoxic chemotherapy. - Postoperative nausea and vomiting: reduces the incidence of nausea and vomiting after surgical procedures. - Radiotherapy‑induced nausea and vomiting: alleviates nausea and vomiting associated with radiation treatment.

Common Side Effects: - Headache: mild to moderate headache. - Constipation: reduced bowel movements. - Diarrhea: loose stools. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - QT prolongation: potential cardiac rhythm changes that may lead to arrhythmia. - Severe allergic reaction: anaphylaxis, rash, or swelling. - Serotonin syndrome: rare but serious condition when combined with other serotonergic agents.

Before prescribing ondansetron, consider the following precautions. - Cardiac monitoring: assess ECG in patients with known cardiac disease or electrolyte imbalance. - Electrolyte imbalance: correct potassium or magnesium deficiencies prior to use. - Concomitant serotonergic drugs: avoid or monitor closely for serotonin syndrome. - Pregnancy: use only if the potential benefit justifies the potential risk, as safety is not established. - Liver impairment: dose adjustment may be required in severe hepatic dysfunction. - Store at ambient temperature: keep below 25°C, retain in the original packaging, and protect from moisture.

Ondansetron may interact with several medicines; review patient medication lists carefully. Major Interactions (Avoid): - Apomorphine: can cause profound hypotension and loss of consciousness. - Certain antiarrhythmics (e.g., quinidine): increase risk of QT prolongation. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise ondansetron plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce ondansetron effectiveness. - Anticholinergic drugs: may diminish the antiemetic effect of ondansetron.